The global mRNA therapeutics market size is evaluated at USD 20.83 billion in 2025 and is forecasted to hit around USD 42.64 billion by 2034, growing at a CAGR of 8.28% from 2025 to 2034. The North America market size was accounted at USD 7.32 billion in 2024 and is expanding at a CAGR of 8.73% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: MRNA Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. MRNA Therapeutics Market, by Application
8.1.1 Oncology
8.1.1.1. Market Revenue and Forecast
8.1.2. Respiratory Diseases
8.1.2.1. Market Revenue and Forecast
8.1.3. Infectious Diseases
8.1.3.1. Market Revenue and Forecast
8.1.4. Others
8.1.4.1. Market Revenue and Forecast
9.1. MRNA Therapeutics Market, by Type
9.1.1. Prophylactic Vaccines
9.1.1.1. Market Revenue and Forecast
9.1.2. Therapeutic Vaccines
9.1.2.1. Market Revenue and Forecast
10.1. MRNA Therapeutics Market, by End User
10.1.1. Hospitals & Clinics
10.1.1.1. Market Revenue and Forecast
10.1.2. Research Organizations
10.1.2.1. Market Revenue and Forecast
10.1.3. Other
10.1.3.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Application
11.1.2. Market Revenue and Forecast, by Type
11.1.3. Market Revenue and Forecast, by End User
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Application
11.1.4.2. Market Revenue and Forecast, by Type
11.1.4.3. Market Revenue and Forecast, by End User
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Application
11.1.5.2. Market Revenue and Forecast, by Type
11.1.5.3. Market Revenue and Forecast, by End User
11.2. Europe
11.2.1. Market Revenue and Forecast, by Application
11.2.2. Market Revenue and Forecast, by Type
11.2.3. Market Revenue and Forecast, by End User
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Application
11.2.4.2. Market Revenue and Forecast, by Type
11.2.4.3. Market Revenue and Forecast, by End User
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Application
11.2.5.2. Market Revenue and Forecast, by Type
11.2.5.3. Market Revenue and Forecast, by End User
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Application
11.2.6.2. Market Revenue and Forecast, by Type
11.2.6.3. Market Revenue and Forecast, by End User
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Application
11.2.7.2. Market Revenue and Forecast, by Type
11.2.7.3. Market Revenue and Forecast, by End User
11.3. APAC
11.3.1. Market Revenue and Forecast, by Application
11.3.2. Market Revenue and Forecast, by Type
11.3.3. Market Revenue and Forecast, by End User
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Application
11.3.4.2. Market Revenue and Forecast, by Type
11.3.4.3. Market Revenue and Forecast, by End User
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Application
11.3.5.2. Market Revenue and Forecast, by Type
11.3.5.3. Market Revenue and Forecast, by End User
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Application
11.3.6.2. Market Revenue and Forecast, by Type
11.3.6.3. Market Revenue and Forecast, by End User
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Application
11.3.7.2. Market Revenue and Forecast, by Type
11.3.7.3. Market Revenue and Forecast, by End User
11.4. MEA
11.4.1. Market Revenue and Forecast, by Application
11.4.2. Market Revenue and Forecast, by Type
11.4.3. Market Revenue and Forecast, by End User
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Application
11.4.4.2. Market Revenue and Forecast, by Type
11.4.4.3. Market Revenue and Forecast, by End User
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Application
11.4.5.2. Market Revenue and Forecast, by Type
11.4.5.3. Market Revenue and Forecast, by End User
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Application
11.4.6.2. Market Revenue and Forecast, by Type
11.4.6.3. Market Revenue and Forecast, by End User
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Application
11.4.7.2. Market Revenue and Forecast, by Type
11.4.7.3. Market Revenue and Forecast, by End User
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Application
11.5.2. Market Revenue and Forecast, by Type
11.5.3. Market Revenue and Forecast, by End User
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Application
11.5.4.2. Market Revenue and Forecast, by Type
11.5.4.3. Market Revenue and Forecast, by End User
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Application
11.5.5.2. Market Revenue and Forecast, by Type
11.5.5.3. Market Revenue and Forecast, by End User
12.1. Alnylam Pharmaceuticals
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Arcturus Therapeutics
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Argos Therapeutics Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. AstraZeneca plc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. BioNTech SE
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. CRISPR Therapeutics AG
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Curevac AG
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Etherna Immunotherapies
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Ethris GMBH
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. GSK plc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample